The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis
Introduction: Cetuximab and panitumumab has been used clinically to treat metastatic colorectal cancer for over 15 years. Before the treatment is given, it is necessary to determine the KRAS mutation status because it would lead to drug resistance. tumor tissue sample is traditionally used for genotyping of cancer. In recent years, the biopsy sample liquid has been intensively investigated as a substitute for tumor tissue samples for non-invasive and better presentation of tumor heterogeneity.
The purpose of this study was to systematically summarize the accuracy of the measurement of KRAS mutations in colorectal cancer using the cell-free DNA in the sample liquid biopsy, the tumor tissue samples as reference (gold standard). Methods and analysis: We will find literature in the following databases: Pubmed, Embase, and the Cochrane Library. systemic review and meta-analysis will be conducted to summarize the accuracy of the measurement of KRAS mutations in colorectal cancer using biopsy samples of liquid and subgroup analyzes will be performed on different testing platforms, and in colorectal cancer metastatic and non-metastatic. Timeline: The research will begin on June 1, 2020, and is expected to be completed date of 1 November 2020.
Ethics and deployment: Ethics approval will not be required because the data obtained and analyzed in this study will not be in each patient. The results of the research will be disseminated as an official publication in peer-reviewed
A PCR-based NGS protocol for whole genome sequencing of West Nile virus 2 direct descendant of biological specimens.
Lineage 2 West Nile virus (WNV) strain has been involved in a severe outbreak of encephalitis in humans and equines which are in Europe. WNV molecular characterization is important for the development of diagnostic tests, and to obtain molecular information, which is necessary for epidemiological investigations in areas at risk of virus transmission.
For whole-genome sequencing of strains of WNV lineage 2, directly from biological specimens, PCR-based NGS protocol developed. This method is applied to the WNV-positive specimens were obtained from animals, human and mosquito hosts in Greece. Outcomes of the application shows that, even in the case of a low viral titers, developed PCR-based NGS approach capable of providing whole genome sequence of strain lineage 2 WNV.
The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis
The latest trends in molecular diagnostics yeast infection: PCR for NGS.
The incidence of opportunistic yeast infections in humans has increased in recent years. These infections are difficult to treat and diagnose, partly because the large number and wide variety of species that can be underlying infection.
Moreover, resistance to one or more of antifungal drugs in a strain that infects more and more reported, severely limiting therapeutic options and to show the need for rapid detection of infecting agents and the profile of its drug susceptibility.
Current methods for species identification of constraints and shortage of sensitivity and specificity were satisfactory, and often require a previous culture of the infecting agent, which delays diagnosis.
Recently developed high-throughput technologies such as next-generation sequencing or proteomics opens a completely new way to diagnose more sensitive, accurate and rapid pathogenic yeast. These approaches are the focus of intensive research, but the translation to the clinic needed to overcome important challenges. In this review, we provide an overview of existing approaches and recently appeared which can be used in the identification of the yeast pathogens and their drug resistance profile.
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF; Recommended dilution: IF:1:50-1:200
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000
Description: The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described.
Description: The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described.
Description: Cluster of Differentiation 79b, is a human gene mapped to 17q23.3. The CD79b protein together with the relatedCD79aprotein, forms a dimer associated with membrane bound immunoglobulin in B-cells, thus forming the B-cell antigen receptor (BCR) which is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). CD79b also enhances phosphorylation of CD79a, possibly by recruiting kinases, or by recruiting proteins which bind to CD79a and protect it from dephosphorylation.
Description: CD79b molecule, immunoglobulin-associated beta, also known as CD79B (Cluster of Differentiation 79B), is a human gene. By fluorescence in situ hybridization, It is mapped to 17q23.3. The CD79B protein together with the related CD79A protein, forms a dimer associated with membrane bound immunoglobulin in B-cells, thus forming the B-cell antigen receptor (BCR) which is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). CD79b also can enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
Description: The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. [UniProt]
Description: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. [UniProt]
Description: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. [UniProt]
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig alpha/Ig beta) is a heterodimer composed of alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79 (also designated Ig chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the BCR signaling reactions by binding to and activating tyrosine kinases.
Description: CD79B is a single-pass type I membrane protein. CD79B contains one Ig-like V-type domain and one ITAM domain. CD79B is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR), which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. CD79B enhances phosphorylation of CD79A, possibly by recruiting kinases that phosphorylate CD79A or by recruiting proteins that bind to CD79A and protect it from dephosphorylation.
Description: A polyclonal antibody for detection of CD79b from Human. This CD79b antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human CD79b
Description: A polyclonal antibody for detection of CD79b from Human. This CD79b antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human CD79b
Description: A polyclonal antibody for detection of CD79b from Human. This CD79b antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human CD79b
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: CD79B Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 155 amino acids (29-159a.a) and having a molecular mass of 17.7kDa. ;CD79B is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Description: A polyclonal antibody against CD79B. Recognizes CD79B from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: Description of target: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sanadwich ELISA;Sensitivity: 1.56 pg/mL
Description: Description of target: Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sanadwich ELISA;Sensitivity: 0.04 ng/mL
Description: CD79B Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 140 amino acids (29-159a.a.) and having a molecular mass of 16.3kDa (Molecular size on SDS-PAGE will appear at approximately 18-28 kDa).;CD79B is expressed with a 9 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Throughout the text we highlight the advantages and disadvantages of each methodology and discuss the most promising developments in their path from bench to bedside.
Kent
